A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B
about
sameAs
Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophagesYeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptorsDirect involvement of the ubiquitin-conjugating enzyme Ubc9/Hus5 in the degradation of IkappaBalphaCoordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinaseIkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase.Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neuronsPhosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuliThe CXXCXXC motif determines the folding, structure and stability of human Ero1-LalphaI kappaB alpha physically interacts with a cytoskeleton-associated protein through its signal response domainMapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradationRegulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factorsDecreased Jun-D and myogenin expression in muscle wasting of human cachexiaThe interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brainEpoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activityTransdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplicationTroglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alphaActivation of nuclear factor-kappaB and not activator protein-1 in cellular response to nickel compounds.Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cellsSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Role of disorder in IκB-NFκB interactionOxidized Hemoglobin Is an Endogenous Proinflammatory Agonist That Targets Vascular Endothelial CellsThe immunoproteasome and viral infection: a complex regulator of inflammationNF-kappaB is involved in the regulation of CD154 (CD40 ligand) expression in primary human T cellsActivation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytesStimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathwaySignal-induced degradation of I kappa B alpha requires site-specific ubiquitinationProteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.Effects of IkappaBalpha and its mutants on NF-kappaB and p53 signaling pathways.Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis.Role of the ubiquitin proteasome system in renal cell carcinoma.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.AP-1 factors play an important role in transformation induced by the v-rel oncogene.Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activityThe proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in miceNoxa mediates hepatic stellate cell apoptosis by proteasome inhibition.Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsPhase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology GroupMonoubiquitination of nuclear RelA negatively regulates NF-κB activity independent of proteasomal degradation
P2860
Q21296830-BD81FA4F-2E7C-4699-BC8A-1A62904C9C32Q24316214-240824FD-0A4A-40E8-BB97-6E0DE1195B39Q24317303-75889285-3D0A-4ACB-A333-421E67E55735Q24522867-C1A0492A-19FE-4E8A-9A9D-9363CE64ABF9Q24532221-E1989112-8AA5-4179-A80C-DF98A7EBCD9FQ24563145-1CF74635-E625-43AC-88BA-B56432556931Q24568220-9773A896-AB5F-4FD9-A7FC-277AA8C1633BQ24599012-8DA05B3A-5E68-4077-BE0D-7B786FF121AAQ24643936-86717EA4-D74F-4536-A125-3CDC4278DF9BQ24650561-AFE4DFB5-EB73-4B3A-AB2B-CEDF3B97EF68Q24651506-37A69228-735D-4CF2-8196-FB4652FB9EA5Q24654557-8969661E-99B7-4A40-9038-22CA08CB4E3BQ24675638-EF2BFEEC-1634-484A-B80E-1BAFF83AE5EFQ24679238-653E2F96-A9EB-4D36-B2F7-3F6EB7F709A3Q24681560-7947CBFB-3E07-4DC8-941A-920BD5D6BD83Q24793384-E0BB3A4A-4940-4818-B08E-3CD7B3FE3560Q24812598-2F008C9D-9B47-459E-8F26-8BEF3441B4DBQ24814434-F66F60EE-99D7-488C-A239-4AF9D0811DFBQ26740359-D8D79903-4CBA-4482-A23A-095A25F438EDQ26865182-8635E62F-72D4-456E-B747-F6ADB8504BA6Q27490449-D2790BF7-4A02-4707-8634-06E3A75F83CCQ27694656-198BBB65-2A6E-44BF-AF72-0B5DF40A6BAAQ28347536-5DE5E1BA-2E89-451A-8AFC-5952ABAFAAFAQ28366026-9C582678-7403-47A3-B7D5-19BC45E18BC0Q28615591-4620FA56-28D6-43A1-B4C9-6F6BCF1020CFQ28615601-3B1F6C35-341B-4D2F-8777-8365B149F39AQ30502900-DE7F2D9A-E877-417F-9505-429785674421Q33262194-D454E3C9-65E4-4412-BEC6-713C4AC0A0E9Q33264524-98B667D5-DC8B-469F-9ACF-ED063C54543FQ33307879-DE218AB9-6844-4C5B-944F-0AF33B43B2A5Q33482818-B961E817-8B49-4E9D-B3AB-2B02755D3C0FQ33786606-EC90F9C0-D14B-4744-B83B-50734E0BCC54Q33890400-A5F5FF4A-36A7-42CC-955E-F800D19E0413Q33957447-D297A39C-B8D3-4E38-8B52-DDE3D0B5CA45Q33993411-B675B739-2F43-44D8-B31F-8101BBEFF3F6Q34070935-08395287-6CE5-4EE0-923A-73D8EE5C52C6Q34182208-21275930-D279-487E-BD3A-DF7FAFE93E3FQ34218976-102A69DA-BC7B-4DD4-84A5-FE9420ED3549Q34225158-FAA44B84-8F2A-473B-9F1F-C13698A87BBBQ34248458-E5939200-ED07-48C9-B799-A2D34776FF7A
P2860
A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B
description
1994 nî lūn-bûn
@nan
1994 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@ast
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@en
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@nl
type
label
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@ast
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@en
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@nl
prefLabel
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@ast
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@en
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@nl
P2093
P2860
P3181
P1433
P1476
A proteasome inhibitor prevent ...... t is still bound to NF-kappa B
@en
P2093
Baeuerle PA
Traenckner EB
P2860
P304
P3181
P356
10.1002/J.1460-2075.1994.TB06878.X
P407
P577
1994-11-01T00:00:00Z